Revolutionizing the AI-Driven Drug Discovery: Insilico Medicine granted FDA Orphan Drug Designation for the treatment of Idiopathic Pulmonary Fibrosis.
According to Globe Newswire, the FDA has approved Orphan Drug Designation to INSO18_55 for treating IPF (Idiopathic Pulmonary Fibrosis). This approval represents a significant breakthrough, showcasing how AI-Driven Drug Discovery is revolutionizing the pharmaceutical landscape. The advancements made by Insilico…